Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Cefapirin

Related Products

Hot Products

Name

Cefapirin

EINECS 244-466-5
CAS No. 21593-23-7 Density 1.573 g/cm3
PSA 179.99000 LogP 1.25360
Solubility N/A Melting Point >135 °C (dec.)
Formula C17H17N3O6S2 Boiling Point 783.902 °C at 760 mmHg
Molecular Weight 423.47 Flash Point 427.889 °C
Transport Information N/A Appearance Beige Solid
Safety Risk Codes N/A
Molecular Structure Molecular Structure of 21593-23-7 (cefapirin) Hazard Symbols N/A
Synonyms

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,3-[(acetyloxy)methyl]-8-oxo-7-[[(4-pyridinylthio)acetyl]amino]-, (6R-trans)-;7-[2-(4-Pyridylthio)acetamido]cephalosporanic acid;Cephapirin;Cephapirine;Cephaprin;

Article Data 11

Cefapirin Specification

The Cefapirin, with the CAS registry number 21593-23-7, is also known as 7-[2-(4-Pyridylthio)acetamido]cephalosporanic acid. It belongs to the product categories of Aromatics; Chiral Reagents; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds. Its EINECS number is 244-466-5. This chemical's molecular formula is C17H17N3O6S2 and molecular weight is 423.47. What's more, its systematic name is (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-{[(4-pyridinylsulfanyl)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Its classification codes are: (1)Anti-Bacterial Agents; (2)Anti-Infective Agents; (3)Antibiotics; (4)Drug / Therapeutic Agent; (5)Human Data. It is a kind of cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms. 

Physical properties of Cefapirin are: (1)ACD/LogP: -0.412; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -3.17; (4)ACD/LogD (pH 7.4): -4.11; (5)ACD/BCF (pH 5.5): 1.00 ; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 1.00; (8)ACD/KOC (pH 7.4): 1.00; (9)#H bond acceptors: 9; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 8; (12)Polar Surface Area: 176.5 Å2; (13)Index of Refraction: 1.689; (14)Molar Refractivity: 102.748 cm3; (15)Molar Volume: 269.145 cm3; (16)Polarizability: 40.733×10-24cm3; (17)Surface Tension: 83.9 dyne/cm; (18)Density: 1.573 g/cm3; (19)Flash Point: 427.889 °C; (20)Enthalpy of Vaporization: 119.627 kJ/mol; (21)Boiling Point: 783.902 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.

You can still convert the following datas into molecular structure:
(1)SMILES: O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)CSc3ccncc3)COC(=O)C)C(=O)O
(2)Std. InChI: InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
(3)Std. InChIKey: UQLLWWBDSUHNEB-CZUORRHYSA-N

The toxicity data is as follows:  

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo intravenous 514ug/kg/9D-I (.514mg/kg) LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" Drug Intelligence and Clinical Pharmacy. Vol. 19, Pg. 553, 1985.
mouse LD50 intraperitoneal 8899mg/kg (8899mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
mouse LD50 intravenous > 7602mg/kg (7602mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
mouse LD50 oral 26088mg/kg (26088mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: IRRITABILITY

BEHAVIORAL: ATAXIA
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
mouse LD50 subcutaneous 13556mg/kg (13556mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
rat LD50 intraperitoneal 7850mg/kg (7850mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
rat LD50 intravenous 6048mg/kg (6048mg/kg) SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE"

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
rat LD50 oral 16356mg/kg (16356mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

BEHAVIORAL: IRRITABILITY
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.
rat LD50 subcutaneous > 14400mg/kg (14400mg/kg) BEHAVIORAL: ANTIPSYCHOTIC Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 279, 1974.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 21593-23-7